The company cites flexibility and ease of use as its main selling points, and is partnering with IVD firms like Randox and R-Biopharm on assay development.
Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
Thermo Fisher will sell Synthego's synthetic guide RNA products under the Invitrogen TrueGuide brand.
The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.
PSS, which develops tools for the IVD space, will supply to Hitachi its nucleic acid isolation system, fully automated diagnostic instruments, and reagents.
Under the terms of the deal, Siemens will expand its kPCR Molecular System menu to include Fast-track's range of tests covering several medical conditions.
The program aims to assist hundreds of people diagnosed with PKU to obtain simple and affordable access to mutation analysis of the PAH gene.
The firms will work to implement MALDI PharmaPulse high-throughput mass spec instrumentation at AMRI's Integrated Drug Discovery Center.
Under the deal, Novartis will access patients who have used Perthera's Precision Cancer Analysis service, which facilitates molecular profiling of cancers.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.